ALLR Allarity Therapeutics, Inc.
$1.52 +14.29%
Healthcare · Pharmaceutical Preparations
Allarity Therapeutics, Inc. (ALLR) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $24 million. Shares last traded at $1.52, 35.3% below their 52-week high. Over the past year the stock is up 87.7%. Net profit margin is -3509.7%, below the peer median of -0.1%.
Market Cap
$24M
Shares Out
15.9M
EPS (TTM)
$-1378.11
P/E Ratio
—
P/S Ratio
75.58
P/B Ratio
3.49
Dividend / Share
—
Dividend Yield
—
52-Week High
$2.35
52-Week Low
$0.77
Volume
8,285
Avg Vol (3m)
4,365.81
Performance
1W
-0.98%
1M
+2.01%
3M
+38.18%
6M
+41.40%
YTD
+33.33%
1Y
+87.65%
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
RSI (14)
50.18
SMA (50)
$1.46
SMA (200)
$1.30
Price vs SMA50
+4.14%
Price vs SMA200
+17.00%
ATR (14)
$0.12
Financials
Revenue
$0M
Net Income
$-11M
Gross Margin
-707.8%
Operating Margin
-3939.1%
Net Margin
-3509.7%
Return on Equity
-162.3%
Return on Assets
-32.2%
Current Ratio
1.23
Debt / Equity
0.39
Revenue Growth (YoY)
—
Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2024 | $-0.73 | 2024-08-05 |
| Q1 2024 | $-22.14 | 2024-05-14 |
| FY 2023 | $-10.26 | 2024-03-08 |
| Q3 2023 | $-18.84 | 2023-11-14 |
| Q2 2024 | $-1336.40 | 2024-08-05 |
| Q1 2024 | $-6356.06 | 2024-05-14 |
Pharmaceutical Preparations peers
ALLR vs 14 industry peers (Pharmaceutical Preparations), by market cap.
P/S vs peers
75.58 / 3.54 med
+2036% premium
Net margin vs peers
-3509.7% / -0.1% med
below median
1–14 of 14
| LLY | Lilly (Eli) | $1.04T | 50.16 | 15.88 | 31.7% | -1.17% |
| JNJ | Johnson & Johnson | $549.8B | 20.51 | 5.84 | 28.5% | -2.42% |
| ONC | Beone Medicines Ltd. | $390.6B | 1361.26 | 73.10 | 5.4% | +2.83% |
| ABBV | AbbVie | $382.5B | 90.51 | 6.25 | 6.9% | -2.16% |
| MRK | Merck | $281.6B | 15.43 | 4.33 | 28.1% | -1.30% |
| ABT | Abbott Laboratories | $154.3B | 23.65 | 3.48 | 14.7% | +0.09% |
| PFE | Pfizer | $143.7B | 18.50 | 2.30 | 12.4% | -2.89% |
| VRTX | Vertex Pharmaceuticals | $114.6B | 28.99 | 9.55 | 32.9% | -1.63% |
| BMY | Bristol Myers Squibb | $110.3B | 15.63 | 2.29 | 14.6% | -2.35% |
| REGN | Regeneron Pharmaceuticals | $63.4B | 14.08 | 4.42 | 31.4% | +0.38% |
| ALNY | Alnylam Pharmaceuticals | $36.9B | 117.57 | 9.93 | 8.4% | -1.66% |
| TEVA | Teva Pharmaceutical Industries Ltd | $36.6B | 25.98 | 2.12 | 8.2% | -3.33% |
| ZTS | Zoetis | $33.1B | 12.37 | 3.49 | 28.2% | +2.09% |
| RPRX | Royalty Pharma Plc | $23.1B | 30.02 | 9.73 | 32.4% | -1.30% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.